Page 348 - Glucose Monitoring Devices

References 355

[104] Messer LH, Forlenza GP, Sherr JL, Wadwa RP, Buckingham BA, Weinzimer SA, et al.
Optimizing hybrid closed-loop therapy in adolescents and emerging adults using the
MiniMed 670G system. Diabetes Care 2018;41(4):789e96.
[105] Stone MP, Agrawal P, Chen X, Liu M, Shin J, Cordero TL, et al. Retrospective analysis
of 3-month real-world glucose data after the MiniMed 670G system commercial
launch. Diabetes Technology and Therapeutics 2018;20(10):689e92.
[106] MiniMed(TM) 670G system real-world data on 8 million patient days shows 71
percent time in range across all age groups. Medtronic; 2019 [press release]. Online.
[107] Berget CML, Vigers T, Wadwa RP, Slover RH, Pyle L, Driscoll KA, Forlenza GP.
Hybrid closed loop therapy in the real world: 6 month clinical observation of youth
with type 1 diabetes. Berlin, Germany: Advanced Technologies and Treatments of
Diabetes; 2019.
[108] Goodwin WG, Lyons J, Oladunjoye A, Steil G. Challenges in implementing hybrid
closed loop insulin pump therapy (Medtronic 670G) in a “real world” clinical
setting. The Journal of Clinical Endocrinology and Metabolism 2019;3(1). OR14-O15.
[109] Lal RBM, Maahs DM, Buckingham BA, Jeannine L, Chmielewski A, Peterson K,
Wilson DM. 670G clinical experience. San Francisco, CA: American Diabetes Asso-
ciation Annual Scientific Meeting; 2019.
[110] Akturk HKGD, Joseph H, Garg SK, Snell-Bergeon JK. Improvement in time-in-range
(TIR) with real-life use of hybrid closed-loop system in ptients with type 1 diabetes.
San Francisco, California: American Diabetes Association Annual Scientific Meeting;
2019.
[111] Newswanger B, Ammons S, Phadnis N, Ward WK, Castle J, Campbell RW, et al.
Development of a highly stable, nonaqueous glucagon formulation for delivery via
infusion pump systems. Journal of Diabetes Science and Technology 2015;9(1):
24e33.
[112] Riddle MC, Nahra R, Han J, Castle J, Hanavan K, Hompesch M, et al. Control of
postprandial hyperglycemia in type 1 diabetes by 24-hour fixed-dose coadministration
of pramlintide and regular human insulin: a randomized, two-way crossover study.
Diabetes Care 2018;41(11):2346e52.
[113] Messer LH, Forlenza GP, Wadwa RP, Weinzimer SA, Sherr JL, Hood KK, et al. The
dawn of automated insulin delivery: a new clinical framework to conceptualize insulin
administration. Pediatric Diabetes 2017;19(1):14e7.
[114] Messer LH, Berget C, Forlenza GP. A clinical guide to advanced diabetes devices and
closed-loop systems using the CARES paradigm. Diabetes Technology and Therapeu-
tics 2019;21(8):462e9.
[115] Cescon M, DeSalvo DJ, Ly TT, Maahs DM, Messer LH, Buckingham BA, et al. Early
detection of infusion set failure during insulin pump therapy in type 1 diabetes. Journal
of Diabetes Science and Technology 2016;10(6):1268e76.
[116] Facchinetti A, Del Favero S, Sparacino G, Cobelli C. An online failure detection
method of the glucose sensor-insulin pump system: improved overnight safety of
type-1 diabetic subjects. IEEE Transactions on Biomedical Engineering 2013;60(2):
406e16.
[117] Facchinetti A, Del Favero S, Sparacino G, Cobelli C. Detecting failures of the glucose
sensor-insulin pump system: improved overnight safety monitoring for type-1
diabetes. Conference Proceedings: Annual International Conference of the IEEE
Engineering in Medicine and Biology Society IEEE Engineering in Medicine and
Biology Society Annual Conference 2011;2011:4947e50.